Cargando…
Oral delivery of xenon for cardiovascular protection
Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological and myocardial protection without side effects. The conventional method of Xe delivery by inhalation is not feasible on a chronic basis. We have developed an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773773/ https://www.ncbi.nlm.nih.gov/pubmed/31575906 http://dx.doi.org/10.1038/s41598-019-50515-3 |
_version_ | 1783455950125924352 |
---|---|
author | Yin, Xing Moody, Melanie R. Hebert, Valeria Klegerman, Melvin E. Geng, Yong-Jian Dugas, Tammy R. McPherson, David D. Kim, Hyunggun Huang, Shao-Ling |
author_facet | Yin, Xing Moody, Melanie R. Hebert, Valeria Klegerman, Melvin E. Geng, Yong-Jian Dugas, Tammy R. McPherson, David D. Kim, Hyunggun Huang, Shao-Ling |
author_sort | Yin, Xing |
collection | PubMed |
description | Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological and myocardial protection without side effects. The conventional method of Xe delivery by inhalation is not feasible on a chronic basis. We have developed an orally deliverable, effective Xe formulation for long-term administration. We employed 2-hydroxypropyl)-β-cyclodextrin (HPCD), which was dissolved in water to increase the Xe concentration in solution. The beneficial effects of long-term oral administration of Xe-enriched solutions on cardiovascular function were evaluated in vivo. HPCD increased Xe solubility from 0.22 mM to 0.67 mM (3.8-fold). Aged ApoE knockout mice fed high-fat diet for 6 weeks developed hypertension, and myocardial hypertrophy with impaired cardiac function. Oral Xe prevented this ischemic damage, preserving normal blood pressure, while maintaining normal left ventricular mass and wall thickness. This novel formulation allows for gastrointestinal delivery and cardiovascular stabilization. |
format | Online Article Text |
id | pubmed-6773773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-67737732019-10-04 Oral delivery of xenon for cardiovascular protection Yin, Xing Moody, Melanie R. Hebert, Valeria Klegerman, Melvin E. Geng, Yong-Jian Dugas, Tammy R. McPherson, David D. Kim, Hyunggun Huang, Shao-Ling Sci Rep Article Cardiac hypertrophy often causes impairment of cardiac function. Xenon (Xe), a naturally occurring noble gas, is known to provide neurological and myocardial protection without side effects. The conventional method of Xe delivery by inhalation is not feasible on a chronic basis. We have developed an orally deliverable, effective Xe formulation for long-term administration. We employed 2-hydroxypropyl)-β-cyclodextrin (HPCD), which was dissolved in water to increase the Xe concentration in solution. The beneficial effects of long-term oral administration of Xe-enriched solutions on cardiovascular function were evaluated in vivo. HPCD increased Xe solubility from 0.22 mM to 0.67 mM (3.8-fold). Aged ApoE knockout mice fed high-fat diet for 6 weeks developed hypertension, and myocardial hypertrophy with impaired cardiac function. Oral Xe prevented this ischemic damage, preserving normal blood pressure, while maintaining normal left ventricular mass and wall thickness. This novel formulation allows for gastrointestinal delivery and cardiovascular stabilization. Nature Publishing Group UK 2019-10-01 /pmc/articles/PMC6773773/ /pubmed/31575906 http://dx.doi.org/10.1038/s41598-019-50515-3 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Yin, Xing Moody, Melanie R. Hebert, Valeria Klegerman, Melvin E. Geng, Yong-Jian Dugas, Tammy R. McPherson, David D. Kim, Hyunggun Huang, Shao-Ling Oral delivery of xenon for cardiovascular protection |
title | Oral delivery of xenon for cardiovascular protection |
title_full | Oral delivery of xenon for cardiovascular protection |
title_fullStr | Oral delivery of xenon for cardiovascular protection |
title_full_unstemmed | Oral delivery of xenon for cardiovascular protection |
title_short | Oral delivery of xenon for cardiovascular protection |
title_sort | oral delivery of xenon for cardiovascular protection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773773/ https://www.ncbi.nlm.nih.gov/pubmed/31575906 http://dx.doi.org/10.1038/s41598-019-50515-3 |
work_keys_str_mv | AT yinxing oraldeliveryofxenonforcardiovascularprotection AT moodymelanier oraldeliveryofxenonforcardiovascularprotection AT hebertvaleria oraldeliveryofxenonforcardiovascularprotection AT klegermanmelvine oraldeliveryofxenonforcardiovascularprotection AT gengyongjian oraldeliveryofxenonforcardiovascularprotection AT dugastammyr oraldeliveryofxenonforcardiovascularprotection AT mcphersondavidd oraldeliveryofxenonforcardiovascularprotection AT kimhyunggun oraldeliveryofxenonforcardiovascularprotection AT huangshaoling oraldeliveryofxenonforcardiovascularprotection |